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This Month in the Journal
Power to Map QTL in General Pedigrees, by Yu et al.
(p. 17)
There are several different methods that have been pro-
posed for quantitative-trait–loci (QTL) analysis. How,
then, should one decide which method to use? To help
researchers make this decision, Yu et al. compared re-
gression and maximum-likelihood methods for different
family structures. The emphasis was on nuclear families
consisting of several siblings and arbitrary general pedi-
grees. Four methods were considered: the Haseman-Els-
ton (HE) and Visscher-Hopper (VH) regressionmethods,
a maximum-likelihood variance-components method,
and a novel regression method (SR) proposed by Sham
et al. (2002) (see reference in Yu et al.) for general pedi-
grees. Theoretical derivations have been used in the past
to compare the power of different methods. To do this,
assumptions are made about the distributions of the test
statistics that, if true, would mean that the relative power
of different tests can be determined through calculations
of the expected test statistic under the alternative hy-
pothesis of linkage. Yu et al. show that, when the family
size is large, test statistics from regression-basedmethods
do not follow the assumed distribution. This makes con-
clusions regarding relative power based on average test
statistics inaccurate. Instead, Yu et al. advocate the use
of empirical power for comparisons between the QTL-
mapping methods. This type of comparison shows that,
in contrast to what has been suggested elsewhere on the
basis of theoretical calculations, the SR method is not
necessarily more powerful than the variance-compo-
nents methods for large sibships and general pedigrees.
Cladistic Linkage Disequilibrium Mapping, by Durrant
et al. (p. 35)
To take advantage of the reams of data that can be
gained from high-throughput genotyping in population-
based samples, Durrant et al. propose a novel disease-
gene–mapping method, based on cladistic analysis, that
can be used for whole-genome scans, ﬁne mapping, or
candidate-gene studies. The idea behind this method is
that disease chromosomes that share a mutation should
have a more recent common ancestor—and therefore
should be more similar—than control chromosomes. This
similarity is quantiﬁed on the basis of the proportion of
matching markers within sliding windows of SNPs and
is expressed as a cladogram that is constructed to mini-
mize haplotype diversity within clades. Under the null
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hypothesis of no association, the haplotypes in each clus-
ter in the cladogram have an equal chance of being car-
ried by a case or by a control. Durrant et al. developed
two haplotype-based logistic regression analyses based on
this idea and used simulations to show that the power of
each is greatly increased, in a variety of situations, over
that for a single locus-based test of association. In ad-
dition, by use of a real data set of cystic ﬁbrosis cases
and controls, their method assigned the strongest signal
of association to a window of markers centered very
near to the DF508 mutation, the most common in the
sample. Through use of this type of analysis, genotypes
at unlinked markers can be incorporated as covariates
to control for population stratiﬁcation, which is a gen-
eral concern in case-control studies. Currently, this clad-
istic approach uses a Bonferroni correction to control for
multiple testing, on the basis of the number of windows
and the partitions of haplotypes in the cladogram. The
power of the approach might be increased even further
through use of less conservative correction procedures.
Whole-Genome Scan Using SNP Arrays, by John et al.
(p. 54)
There is a lot of excitement surrounding the possibility
that SNP-based linkage studies may be faster and more
powerful than microsatellite-based ones because of the
development of high-throughput SNP-genotyping tech-
nologies and dense SNP-based maps. The question now
is: will this prediction hold true? You might remember
an article by Middleton et al., in our May issue (Am J
HumGenet 74:886–897), in which a SNP-based genome
scan for bipolar disorder yielded more-precise linkage in-
formation than did a microsatellite-based scan on the
same sample. In this issue, John et al. report similar
results from a comparison of the two approaches to ﬁnd
loci involved in rheumatoid arthritis. Moreover, they
tested several possible explanations for the discrepancies
in results, including differences in the genotyping error
rates, the maps used in the analyses, and the information
content of the marker sets. The factor with the largest
effect proved to be the higher information content of
the SNP array, compared with the microsatellites. This
work adds to the evidence that SNP-based linkage analy-
sis will be a useful approach for gene mapping. John et
al. also show that this type of data can be used as a
springboard to association studies. They used their SNP
maps to deﬁne haplotype blocks in the HLA region,
which had the strongest evidence of linkage to arthritis
in the genome scans. Directly under the peak of linkage,
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they found signiﬁcant association of a haplotype with
disease.
Long-Term ERT for Fabry Disease, by Wilcox et al. (p.
65)
Early reports of the success of enzyme replacement ther-
apy for Fabry disease were based on a 20-wk phase 3
clinical trial and 6-mo open-label extension study that
evaluated treatment with recombinant humana-galacto-
sidase A (Fabrazyme). Because of the resultant renal fail-
ure that uniformly develops in untreated patients, ther-
apy for this disorder has focused on the renal pathology,
with clearance of accumulated globotriaosylceramide
(GL-3) to normal levels in the microvascular endothe-
lium as the desired endpoint. During the ﬁrst 6 mo of
the extension study, the vast majority of treated patients
showed clearance of accumulated GL-3 from the kidney
and other tissues, such as the skin and heart. However,
the majority of patients seroconverted within the ﬁrst
few weeks of treatment, and this raised concerns re-
garding the long-term efﬁcacy of this therapy. Wilcox et
al. now report that patients in the extension study have
continued to exhibit normal mean plasma GL-3 levels
and have sustained clearance of GL-3 from capillary
endothelium for 30–36 mo, despite the high prevalence
of seroconversion. Adverse events associated with this
therapy have generally been mild and tolerable and se-
vere events few. Overall, the continued safety and sus-
tained success of enzyme-replacement therapy on the ba-
sis of measures of GL-3 is encouraging. The next step
is to assess its effect on clinical outcomes of Fabry dis-
ease, such as stroke and cardiovascular events. A Fabry
Disease Registry has been established to follow patients
over the long term in order to make these assessments
possible.
Mutation of Human BMP15 Gene, by Di Pasquale et
al. (p. 106)
Since the 2000 report by Galloway et al. (see reference
in Di Pasquale et al.) that mutations of Bmp15 in sheep
were associated with increased ovulation in the hetero-
zygous state and with severe infertility in the homozygous
state, several groups have attempted to ﬁnd infertility-
associated BMP15 mutations in women. Di Pasquale et
al. have ﬁnally found one, in two sisters with hypergo-
nadotropic ovarian failure. This heterozygous missense
mutation was inherited from the unaffected father and
is located in a conserved region encoding the propeptide
region of the BMP15 protein, a member of the trans-
forming growth factor–b (TGF-b) superfamily. This pro-
peptide region is proteolytically cleaved to produce an
active, mature form of the protein, but the processing
does not occur normally with the mutation. The mutant
protein also does not stimulate growth and proliferation
of granulosa cells in culture, as it should, and, in fact,
it abrogates the stimulating effect of the wild-type pro-
tein when the two proteins are added to granulosa cells
in equal amounts. These results suggest that BMP15 is
required for the progression of folliculogenesis in hu-
mans and that mutations in this gene may be an expla-
nation for some cases of female infertility. Its location
on the X chromosome hints that haploinsufﬁciency for
BMP15 could at least partly explain the ovarian dys-
genesis associated with Turner syndrome.
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